A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01424566
Recruitment Status : Completed
First Posted : August 29, 2011
Last Update Posted : July 6, 2016
Otsuka Pharmaceutical Development & Commercialization, Inc.
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : July 2015
  Study Completion Date : December 2015
  Certification/Extension First Submitted : June 24, 2016